Cyclacel Pharmaceuticals (CYCC) Competitors $0.50 -0.12 (-19.20%) (As of 11/4/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends CYCC vs. SXTC, SNOA, VCNX, ENSC, BCDA, SHPH, EVOK, LIXT, CPHI, and ONCTShould you be buying Cyclacel Pharmaceuticals stock or one of its competitors? The main competitors of Cyclacel Pharmaceuticals include China SXT Pharmaceuticals (SXTC), Sonoma Pharmaceuticals (SNOA), Vaccinex (VCNX), Ensysce Biosciences (ENSC), BioCardia (BCDA), Shuttle Pharmaceuticals (SHPH), Evoke Pharma (EVOK), Lixte Biotechnology (LIXT), China Pharma (CPHI), and Oncternal Therapeutics (ONCT). These companies are all part of the "pharmaceutical products" industry. Cyclacel Pharmaceuticals vs. China SXT Pharmaceuticals Sonoma Pharmaceuticals Vaccinex Ensysce Biosciences BioCardia Shuttle Pharmaceuticals Evoke Pharma Lixte Biotechnology China Pharma Oncternal Therapeutics China SXT Pharmaceuticals (NASDAQ:SXTC) and Cyclacel Pharmaceuticals (NASDAQ:CYCC) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, community ranking, institutional ownership, profitability, media sentiment, valuation, risk, dividends and analyst recommendations. Do analysts recommend SXTC or CYCC? Cyclacel Pharmaceuticals has a consensus target price of $11.00, indicating a potential upside of 2,078.22%. Given Cyclacel Pharmaceuticals' higher probable upside, analysts clearly believe Cyclacel Pharmaceuticals is more favorable than China SXT Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score China SXT Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) N/ACyclacel Pharmaceuticals 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.33 Which has better earnings & valuation, SXTC or CYCC? China SXT Pharmaceuticals has higher revenue and earnings than Cyclacel Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioChina SXT Pharmaceuticals$1.93M1.01-$3.10MN/AN/ACyclacel Pharmaceuticals$80K13.58-$22.56M-$16.57-0.03 Does the MarketBeat Community prefer SXTC or CYCC? Cyclacel Pharmaceuticals received 105 more outperform votes than China SXT Pharmaceuticals when rated by MarketBeat users. However, 61.65% of users gave China SXT Pharmaceuticals an outperform vote while only 47.58% of users gave Cyclacel Pharmaceuticals an outperform vote. CompanyUnderperformOutperformChina SXT PharmaceuticalsOutperform Votes8261.65% Underperform Votes5138.35% Cyclacel PharmaceuticalsOutperform Votes18747.58% Underperform Votes20652.42% Do insiders & institutionals have more ownership in SXTC or CYCC? 5.0% of China SXT Pharmaceuticals shares are held by institutional investors. Comparatively, 23.6% of Cyclacel Pharmaceuticals shares are held by institutional investors. 4.0% of China SXT Pharmaceuticals shares are held by insiders. Comparatively, 8.0% of Cyclacel Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Is SXTC or CYCC more profitable? China SXT Pharmaceuticals has a net margin of 0.00% compared to Cyclacel Pharmaceuticals' net margin of -21,963.75%. China SXT Pharmaceuticals' return on equity of 0.00% beat Cyclacel Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets China SXT PharmaceuticalsN/A N/A N/A Cyclacel Pharmaceuticals -21,963.75%-1,901.11%-197.11% Which has more volatility & risk, SXTC or CYCC? China SXT Pharmaceuticals has a beta of 1.16, suggesting that its share price is 16% more volatile than the S&P 500. Comparatively, Cyclacel Pharmaceuticals has a beta of 0.56, suggesting that its share price is 44% less volatile than the S&P 500. Does the media refer more to SXTC or CYCC? In the previous week, Cyclacel Pharmaceuticals had 3 more articles in the media than China SXT Pharmaceuticals. MarketBeat recorded 4 mentions for Cyclacel Pharmaceuticals and 1 mentions for China SXT Pharmaceuticals. China SXT Pharmaceuticals' average media sentiment score of 0.00 beat Cyclacel Pharmaceuticals' score of -0.60 indicating that China SXT Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment China SXT Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cyclacel Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Negative SummaryChina SXT Pharmaceuticals beats Cyclacel Pharmaceuticals on 8 of the 15 factors compared between the two stocks. Ad WealthPressCould TSLA reach $500 a share? Free ebook says it’s possible.Even though shares of Tesla are only up 3% this year, one man believes Tesla’s next bull run is just around the corner. In his professional opinion, the share price could reach $500 or more… Now, we understand that may seem far-fetched, but as you’ll see in his new ebook, it’s not as crazy as it may sound. In fact, he argues a Trump presidency could make it happen much faster than you might think. which is why we’re emailing you now… For the time being, he’s giving away his Tesla ebook for free. Inside explains how shares could reach $500 in the near future.To claim your copy, follow this link Get Cyclacel Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CYCC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CYCC vs. The Competition Export to ExcelMetricCyclacel PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.09M$6.76B$5.06B$8.43BDividend YieldN/A7.94%7.52%4.16%P/E Ratio-0.0312.22131.9616.70Price / Sales13.58271.051,683.8276.34Price / CashN/A46.0937.1533.56Price / Book0.895.274.614.98Net Income-$22.56M$151.58M$115.40M$224.69M7 Day Performance-27.86%0.28%-0.26%1.31%1 Month Performance-45.70%14.86%5.74%4.90%1 Year Performance-94.21%36.83%33.81%26.34% Cyclacel Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CYCCCyclacel Pharmaceuticals2.8343 of 5 stars$0.51-19.2%$11.00+2,078.2%-92.8%$1.09M$80,000.00-0.0314Upcoming EarningsSXTCChina SXT Pharmaceuticals0.2489 of 5 stars$0.53-5.4%N/A-77.1%$2.15M$1.93M0.0090News CoverageSNOASonoma Pharmaceuticals0.6131 of 5 stars$2.79+4.1%N/A+1,400.8%$2.57M$12.73M-0.27180Upcoming EarningsVCNXVaccinex1.373 of 5 stars$2.95+5.7%N/A-77.3%$5.10M$356,000.00-0.0540Upcoming EarningsENSCEnsysce Biosciences1.0102 of 5 stars$0.65+12.1%N/A-34.3%$5.08M$2.23M-0.2310Gap UpHigh Trading VolumeBCDABioCardia2.5744 of 5 stars$2.39+2.6%$25.00+946.0%-60.2%$5.08M$428,000.00-0.4416Gap UpSHPHShuttle Pharmaceuticals1.3318 of 5 stars$1.67-10.7%N/AN/A$4.93MN/A-0.495Upcoming EarningsGap DownEVOKEvoke Pharma0.7226 of 5 stars$5.80-0.9%N/A-59.4%$4.79M$5.18M-0.364Analyst ForecastGap UpLIXTLixte Biotechnology0.586 of 5 stars$2.02-4.3%N/A-32.7%$4.75MN/A-1.133Positive NewsGap UpCPHIChina PharmaN/A$0.26flatN/A-46.1%$4.44M$7.01M0.00250ONCTOncternal Therapeutics2.4467 of 5 stars$1.50+2.7%$20.00+1,233.3%-79.2%$4.44M$790,000.00-0.1230Analyst Forecast Related Companies and Tools Related Companies China SXT Pharmaceuticals Competitors Sonoma Pharmaceuticals Competitors Vaccinex Competitors Ensysce Biosciences Competitors BioCardia Competitors Shuttle Pharmaceuticals Competitors Evoke Pharma Competitors Lixte Biotechnology Competitors China Pharma Competitors Oncternal Therapeutics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CYCC) was last updated on 11/4/2024 by MarketBeat.com Staff From Our Partners2 sentences that change everything you THOUGHT you knew about tradingIf you're like most people, on Friday morning you'll probably follow your set routine: Wake up... eat breakfas...Investing Daily | SponsoredBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | Sponsored625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored[Urgent] Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it a...Paradigm Press | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredA Totally New ‘Income Coin’Buckle up… Because this might shatter everything you thought you knew about "income trading." In fact, i...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cyclacel Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cyclacel Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
